SomaLogic

SomaLogic was founded in 2000 by Larry Gold, who served as both Chairman of the Board of Directors and as the company’s first CEO. In 2013, Byron Hewett was appointed as CEO,{{cite web|url=http://www.innovationews.com/INterview-with-Bryron-Hewett-CEO-of-SomaLogic/|title=INterview with Bryron Hewett, CEO of SomaLogic|date=26 January 2016|website=Innovationsews.com|accessdate=26 November 2017}} with Gold continuing to serve as Chairman.{{cite web|url=http://www.xconomy.com/boulder-denver/2013/12/03/somalogic-names-new-ceo-founder-larry-gold-stay-chairman/|title=SomaLogic Names New CEO; Founder Larry Gold to Stay on as Chairman - Xconomy|date=3 December 2013|website=Xconomy.com|accessdate=26 November 2017}} Gold previously founded the pharmaceutical company NeXstar Pharmaceuticals, which merged with Gilead in 1999.{{cite web|url=http://www.gilead.com/news/press-releases/1999/3/gilead-sciences-and-nexstar-pharmaceuticals-to-merge|title=Gilead Sciences and NeXstar Pharmaceuticals to Merge - Gilead|website=Gilead.com|accessdate=26 November 2017}} Hewett stepped down in 2017 and board member Alister Reynolds was appointed the new CEO,{{cite web|url=https://www.genomeweb.com/people-news-alister-reynolds-erik-phelps-and-james-heath|title=People in the News: Alister Reynolds, Erik Phelps, and James Heath|publisher=|accessdate=26 November 2017}} who was replaced by Roy Smythe in 2018.{{Cite web | url=https://huntscanlon.com/slone-partners-finds-new-ceo-for-somalogic/ |title = Slone Partners Finds New CEO for SomaLogic|date = 3 December 2018}}

In July 2022, SomaLogic agreed to acquire Palamedrix Inc, DNA nanotechnology company. {{Cite web |date=2022-07-26 |title=SomaLogic to Acquire DNA Nanotech Firm Palamedrix for up to $52.5M |url=https://www.genomeweb.com/proteomics-protein-research/somalogic-acquire-dna-nanotech-firm-palamedrix-525m |access-date=2022-07-26 |website=Genomeweb |language=en}}

SomaLogic monitors health and disease through the analysis of protein concentration changes in biological samples.{{cite web|url=http://www.xconomy.com/boston/2017/01/06/patientslikeme-nabs-100m-works-to-advance-personalized-medicine/|title=PatientsLikeMe Nabs $100M, Works to Advance Personalized Medicine - Xconomy|date=6 January 2017|website=Xconomy.com|accessdate=26 November 2017}} They developed the SomaScan platform, which allows scientists and researchers to identify protein biomarkers for diseases and conditions, and apply them to drug and diagnostic research and development.{{cite web|url=http://www.bizjournals.com/denver/blog/boosters_bits/2014/11/somalogic-lands-funding-after-novartis-extends.html|title=Somalogic Lands Funding After Novartis Extends|website=Bizjournals.com|accessdate=26 November 2017}} The hypothesis behind the analysis is that different diseases and conditions each have novel protein profiles, including in early stages of onset. As of 2013, the commercial version of the SomaScan platform could identify and quantify 1,129 protein analytes simultaneously. As of 2017, the number had increased to about 4,200.{{cite journal |last1=Cyranoski |first1=David |title=Chinese AI company plans to mine health data faster than rivals |journal=Nature |date=12 January 2017 |volume=541 |issue=7636 |pages=141–142 |doi=10.1038/541141a |pmid=28079091 |bibcode=2017Natur.541..141C |doi-access=free }} The platform is based on modified-aptamer binding technology (“SOMAmers”) that bind to their respective target proteins in order to determine their presence and quantity in a sample.{{cite news |last1=Chi |first1=Kelly Rae |title=High-Density Info |url=https://www.the-scientist.com/lab-tools/high-density-info-37720 |work=The Scientist Magazine |date=March 31, 2014 }}{{cite book |last1=Rastogi |first1=S. C. |last2=Rastogi |first2=Parag |last3=Mendiratta |first3=Namita |title=Bioinformatics Methods And Applications: Genomics Proteomics And Drug Discovery |edition=3rd |date=2008 |publisher=PHI Learning Pvt. Ltd. |isbn=978-81-203-3595-0 |page=362 }}{{cite journal |last1=Keeney |first1=Tracy R. |last2=Bock |first2=Christopher |last3=Gold |first3=Larry |last4=Kraemer |first4=Stephan |last5=Lollo |first5=Bridget |last6=Nikrad |first6=Malti |last7=Stanton |first7=Martin |last8=Stewart |first8=Alex |last9=Vaught |first9=Jonathan D. |last10=Walker |first10=Jeffrey J. |title=Automation of the SomaLogic Proteomics Assay: A Platform for Biomarker Discovery |journal=Journal of the Association for Laboratory Automation |date=December 2009 |volume=14 |issue=6 |pages=360–366 |doi=10.1016/j.jala.2009.05.003 }}

In 2013, SomaLogic partnered with Agilent Technologies to distribute SomaScan systems to American research and educational institutions. It also signed a development deal with Quest Diagnostics to create a blood test for early-stage, non-small-cell lung cancer.{{cite web|url=http://www.xconomy.com/boulder-denver/2013/08/13/somalogic-partners-with-agilent-to-distribute-proteomic-technology/|title=SomaLogic Partners with Agilent to Distribute Proteomic Technology - Xconomy|date=13 August 2013|website=Xconomy.com|accessdate=26 November 2017}}{{cite journal |last1=Powell |first1=Kendall |title=New platform for cataloging hundreds of proteins gets test drive |journal=Nature Medicine |date=8 October 2014 |volume=20 |issue=10 |pages=1082–1083 |doi=10.1038/nm1014-1082 |pmid=25295926 }} It also has partnerships with Otsuka and New England Biolabs.{{cite web|url=http://www.bizjournals.com/denver/print-edition/2011/12/30/people-to-watch-larry-gold.html|title=People to Watch : Larry Gold|website=Bizjournals.com|accessdate=26 November 2017}} In 2016, a study was published that used the SomaLogic system to identify nine biomarker proteins that could predict the risk of a second heart attack in those who have suffered a previous cardiovascular event.{{cite journal |last1=Ganz |first1=Peter |last2=Heidecker |first2=Bettina |last3=Hveem |first3=Kristian |last4=Jonasson |first4=Christian |last5=Kato |first5=Shintaro |last6=Segal |first6=Mark R. |last7=Sterling |first7=David G. |last8=Williams |first8=Stephen A. |title=Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease |journal=JAMA |date=21 June 2016 |volume=315 |issue=23 |pages=2532–41 |doi=10.1001/jama.2016.5951 |pmid=27327800 |doi-access=free }} A study in Circulation also used the 9-protein cardiovascular risk score for early detection of the harmful effects of Torcetrapib.{{cite journal |last1=Williams |first1=Stephen A. |last2=Murthy |first2=Ashwin C. |last3=DeLisle |first3=Robert K. |last4=Hyde |first4=Craig |last5=Malarstig |first5=Anders |last6=Ostroff |first6=Rachel |last7=Weiss |first7=Sophie J. |last8=Segal |first8=Mark R. |last9=Ganz |first9=Peter |title=Improving Assessment of Drug Safety Through Proteomics |journal=Circulation |date=6 March 2018 |volume=137 |issue=10 |pages=999–1010 |doi=10.1161/CIRCULATIONAHA.117.028213 |pmid=28974520 |pmc=5839936 }} In 2016 they also developed a test to diagnose latent tuberculosis, and to predict the progression of the disease after onset.{{cite web|url=https://www.genomeweb.com/proteomics-protein-research/somalogic-developing-tests-diagnose-latent-tuberculosis-predict|title=SomaLogic Developing Tests to Diagnose Latent Tuberculosis, Predict Progression|website=Genomeweb.com|accessdate=26 November 2017}} In 2019, a study was published that used the SomaScan platform to build protein-based models for 11 different health indications: liver fat, kidney filtration, percentage body fat, visceral fat mass, lean body mass, cardiopulmonary fitness, physical activity, alcohol consumption, cigarette smoking, diabetes risk, and primary cardiovascular event risk.{{cite journal |last1=Williams |first1=Stephen A. |last2=Kivimaki |first2=Mika |last3=Langenberg |first3=Claudia |last4=Hingorani |first4=Aroon D. |last5=Casas |first5=J. P. |last6=Bouchard |first6=Claude |last7=Jonasson |first7=Christian |last8=Sarzynski |first8=Mark A. |last9=Shipley |first9=Martin J. |last10=Alexander |first10=Leigh |last11=Ash |first11=Jessica |last12=Bauer |first12=Tim |last13=Chadwick |first13=Jessica |last14=Datta |first14=Gargi |last15=DeLisle |first15=Robert Kirk |last16=Hagar |first16=Yolanda |last17=Hinterberg |first17=Michael |last18=Ostroff |first18=Rachel |last19=Weiss |first19=Sophie |last20=Ganz |first20=Peter |last21=Wareham |first21=Nicholas J. |title=Plasma protein patterns as comprehensive indicators of health |journal=Nature Medicine |date=December 2019 |volume=25 |issue=12 |pages=1851–1857 |doi=10.1038/s41591-019-0665-2 |pmid=31792462 |pmc=6922049 }}

SomaLogic has a long-term partnership with the Novartis Institutes for BioMedical Research, with Novartis taking an ownership stake in SomaLogic in 2014 as a part of the extension of their initial agreement. In 2016, SomaLogic formed a collaborative partnership with Oxford University,{{cite news |title=University and SomaLogic announce agreement for discovery |url=http://www.ox.ac.uk/news/2016-02-08-university-and-somalogic-announce-agreement-discovery |work=University of Oxford |date=8 February 2016 }} and in 2017, it joined the iCarbonX Digital Life Alliance (including an investment by iCarbonX in SomaLogic).{{cite web |url=https://www.genomeweb.com/informatics/chinas-icarbonx-invests-somalogic-grows-medical-data-alliance|title=China's iCarbonX Invests in SomaLogic, Grows Medical Data Alliance|website=Genomeweb.com|accessdate=26 November 2017}}

In 2018, SomaLogic teamed up with the Leeds Centre for Personalised Health and Medicine to test the SomaScan platform in clinical studies in the UK.{{cite web |url=http://www.dailycamera.com/boulder-business/ci_31653273/boulder-somalogic-partner-uk-medical-center |title=Boulder's SomaLogic to partner with UK medical center |publisher=Daily Camera Boulder |date=February 8, 2018 }} That same year, SomaLogic also began to package its insights as diagnostic information for sale to other companies, focusing on proteomic data.{{cite web |url=https://www.genomeweb.com/proteomics-protein-research/somalogic-exploring-new-models-selling-clinical-products-based-somascan#.WvHhSW4vzIU |title=Somalogic Exploring New Models for Selling Clinical Products Based on SomaScan System |publisher=GenomeWeb |date=January 18, 2018 |author=Adam Bonislawski}} In 2019, SomaLogic entered into a new 10-year agreement with Novartis to use the SomaScan proteomics technology in drug discovery and development efforts.“SomaLogic Expands Agreement with Novartis” genomeweb.com. 21 October 2019.

https://www.genomeweb.com/proteomics-protein-research/somalogic-expands-agreement-novartis#.XzLRyRNKi-o

Also that year, SomaLogic began commercially offering health information tests on the SomaScan Platform to prescribing physicians in Colorado.{{Cite web | url=https://www.dailycamera.com/2019/09/04/somalogic-launches-its-firsts-somasignal-tests-in-colorado/ |title = SomaLogic launches its firsts SomaSignal tests in Colorado|date = 5 September 2019}} In 2020, NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, launched a new company, FonesLife Corporation, that will collaborate with SomaLogic to bring proteomic-based health monitoring tests to people in Japan.“NEC Company Collaborating with Somalogic on Proteomics-Based Health Monitoring” 360dx.com. 10 July 2020.

https://www.360dx.com/business-news/nec-company-collaborating-somalogic-proteomics-based-health-monitoring#.XzLWhhNKi-o

{{Reflist}}

• {{Official website|https://www.somalogic.com/}}

Category:2000 establishments in Colorado

Category:Companies based in Boulder, Colorado

Category:Companies formerly listed on the Nasdaq

Category:Cancer organizations based in the United States

Category:Medical and health organizations based in Colorado

Category:Special-purpose acquisition companies

Category:2024 mergers and acquisitions